The baseline barrier dysfunction in these AD patients likely stems from a known pathophysiological cycle: characteristic Th2 immune deviation (e.g., IL-4/IL-13 overexpression) can directly inhibit the synthesis of tight junction proteins like Claudin-1 (24, 25), while other inflammatory mediators may exacerbate epithelial damage (26). The gene discussed is IL13; the disease is Alzheimer disease.